Have clinical trials of NOACs been fair tests of treatments for atrial fibrillation patients?

Patients must live with uncertainty until we have independent scrutiny of key trial data Warfarin reduces the risk of stroke in patients with non-valvular atrial fibrillation but has limitations: a narrow therapeutic window, the need for regular monitoring, and risks of bleeding and drug-drug interactions. Partly because of these limitations, novel oral anticoagulants (NOACs or … More Have clinical trials of NOACs been fair tests of treatments for atrial fibrillation patients?